林水宾

收藏

转化医学研究中心

中山大学附属第一医院（三级甲等）

林水宾

 医生简介

研究方向：

研究专注于肿瘤、干细胞、表观遗传学和RNA生物学等方向，致力于鉴定肿瘤新标记物和治疗靶点，开发针对肿瘤和干细胞相关的发育疾病的诊疗干预新方法等转化医学研究。主要研究方向：1）RNA修饰对肿瘤和干细胞的调控功能和相关机理；2）发育和再生疾病的RNA表观遗传学研究；3）基于RNA的疾病诊断治疗干预研究。以（共同）通讯/第一作者在Nature (2018), Nature Metabolism (2022), Molecular Cell (2021,2018,2016), Nature Protocols (2019), Nature Communications (2022,2018), Advanced Science (2022), Molecular Therapy (2021), Clinical and Translational Medicine (2021), Nature Reviews Cancer(2015) 等杂志发表论文20余篇。论文总被引用次数超过5000次。主持国自然优秀青年基金，面上项目2项、广东省杰出青年基金，以及美国Damon Runyon Cancer Research Foundation、Alex's Lemonade Stand Foundation等多项科研基金。

主要教育和工作经历：

000-2004   学士   厦门大学国家生物学人才培养基地班

2004-2007   硕士   厦门大学生命科学学院，生化与分子生物学系

2007-2012   博士   美国佛罗里达大学医学院（College of Medicine, University of Florida, USA）

2012-2017  博士后  哈佛医学院/波士顿儿童医院 (Harvard Medical School/Boston Children’s Hospital)

2017-至今  研究员  中山大学附属第一医院 转化医学研究中心

社会兼职：

担任美国基因和细胞治疗协会会刊Molecular Therapy 杂志 (Cell Press，IF=12.91)副主编。

代表性论文（*共同第一，#共同通讯）

  1. Peng H*, Chen B*, Wei W*, Guo S*, Han H, Yang C, Ma J, Wang L, Peng S#, Kuang M#, Lin S#. N6-methyladenosine (m6A) in 18S rRNA promotes fatty acid metabolism and oncogenic transformation. Nature Metabolism. 2022 In press.
  2. Han H*, Zheng S*, Lin S. N7-methylguanosine (m7G) tRNA modification: a novel autophagy modulator in cancer. Autophagy. 2022 May 23:1-3. (Commentary)
  3. Han H*, Yang C*, Ma J*, Zhang S*, Zheng S*, Ling R, Sun K, Guo S1 Huang B, Yu Liang Y, Wang L, Chen S, Wang Z, Wei W, Huang Y, Peng H, Jiang YZ, Choe J, Lin S. N7-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis. Nature Communications. 2022 Mar 18;13(1):1478.
  4. Su T, Cheng F, Qi J, Zhang Y, Zhou S, Mei L, Fu S, Zhang F, Lin S#, Zhu G#. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy. Advanced Science. 2022 Jun 16;e2201895.
  5. Zheng S, Han H, Lin S. N6-methyladenosine (m6A) RNA modification in tumor immunity. Cancer Biology & Medicine. 2022 Mar 8;19(4):385-97. (Review)
  6. Wang L, Liang Y, Lin R, Xiong Q, Yu P, Ma Y, Cheng M, Han H, Wang X, Wang G, Liang F, Pei Z, Chen D, Yuan Q#, Jiang YZ#, Lin S#. Mettl5 mediated 18S rRNA N6-methyladenosine (m6A) modification controls stem cell fate determination and neural function. Genes Diseases. 2022 Jan, 9(1): 268-274.
  7. Yang C, Han H, Lin S. RNA epitranscriptomics: A promising new avenue for cancer therapy. Molecular Therapy. 2022 Jan 5;30(1):2-3. (Editorial)
  8. Chen Z*, Zhu W*, Zhu S*, Sun K, Liao J, Liu H, Dai Z, Han H, Ren X, Yang Q, Zheng S, Peng B, Peng S, Kuang M#, Lin S#. METTL1 promotes hepatocarcinogenesis via m7G tRNA modification-dependent translation control. Clinical and Translational Medicine. 2021 Dec;11(12):e661.
  9. Dai Z*, Liu H*, Liao J*, Huang C*, Ren X*, Zhu W, Zhu S, Peng B, Li S, Lai J, Liang L, Xu L, Peng S, Lin S#, Kuang M#. N7-methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression. Molecular Cell. 2021 Aug 19;81(16):3339-3355.
  10. Ma J*, Han H*, Huang Y*, Yang C, Zheng S, Cai T, Bi J, Huang X, Liu R, Huang L, Luo Y#, Li W#, Lin S#. METTL1/WDR4 mediated N7-methylguanosine (m7G) tRNA modifications and m7G codon usage promote mRNA translation and lung cancer progression. Molecular Therapy. 2021 Aug 8:S1525- 0016(21)00399-3.
  11. Han H*, Yang C*, Zhang S*, Cheng M*, Guo S, Zhu Y, Ma Y, Liang Y, Wang L, Zheng S, Wang Z, Chen D#, Jiang YZ#, Lin S#. METTL3 mediated m6A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway. Molecular Therapy-Nucleic Acids. 2021 Jul 21; 26:333-346.
  12. Lin S#, Liu Q, Jiang YZ, Gregory RI#. Nucleotide resolution profiling of m7G tRNA modification by TRAC-Seq. Nature Protocols. 2019 Nov; 14: 3220–3242.
  13. Wu Y*, Xie L*, Wang M, Xiong Q, Guo Y, Liang Y, Li J, Sheng R, Deng P, Wang Y, Zheng R, Jiang Y, Ye L, Chen Q, Zhou X#, Lin S#, Quan Y#. Mettl3-mediated m6A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis. Nature Communications 2018. 9:4772.
  14. Choe J*, Lin S*, Zhang W, Liu Q, Wang L, Ramirez-Moya J, Du P, Kim W, Tang S, Sliz P, Santisteban P, George RE, Richards WG, Wong KK, Locker N, Slack FJ, Gregory RI. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature 2018 Sep;561(7724):556-560
  15. Lin S*, Liu Q*, Lelyveld VS, Choe J, Szostak JW, Gregory RI. The Mettl1/Wdr4 mediated m7G tRNA methylome is required for normal mRNA translation and embryonic stem cell self-renewal and differentiation. Molecular Cell. 2018 Jul 19;71(2):244-255.
  16. Lin S*, Choe J*, Du P, Triboulet R, Gregory RI. The m6A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells. Molecular Cell. 2016 May 5; 62(3):335-345. Highlighted in Mol Cell. 2016 May 5; 62(3):323-324 and Cancer Discov. 2016 Jun; 6(6):572.
  17. Lin S, Gregory RI. MicroRNA biogenesis in cancers. Nature Reviews Cancer. 2015 Jun; 15(6):321-33.
  18. Lin S, Gregory RI. Methyl-transferases modulate RNAs stability in embryonic stem cells. Nature Cell Biology. 2014 Feb;16(2):129-31. (News and Views).
  19. Su T*, Zhang Y*, Valerie K, Wang XY, Lin S#, Zhu G#. STING activation in cancer immunotherapy. Theranostics. 2019 Oct 15;9(25):7759-7771.
  20. Yang F *, Jin H*, Que B*, Chao Y*, Zhang H, Ying X, Zhou Z, Yuan Z, Su J, Wu B, Zhang W, Qi D, Chen D, Min W#, Lin S#, Ji W#.­­­ Dynamic m6A mRNA methylation reveals the role of METTL3-m6A-CDCP1 signaling axis in chemical carcinogenesis. Oncogene 2019 Jun;38(24):4755-4772.
  21. Lin S, Gregory RI. Identification of small molecule inhibitors of Zcchc11 TUTase activity. RNA Biology. 2015;12(8):792-800.
  22. Lin S*, Tian L*, Shen H*, et.al. DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia. Oncogene. 2013 Oct;32(40):4845-53.
  23. Lin S, Shen H, Jin B, et.al. Blockade of Notch Signaling in Muscle Stem Cells Causes Muscular Dystrophic Phenotype and Impaired Muscle Regeneration. Stem Cells. 2013 Apr;31(4):823-8.
  24. Lin S, Shen H, Li JL, et.al. Proteomic and functional analyses reveal the chromatin reader SFMBT1's role in regulating epigenetic silencing and the myogenic gene program. Journal of Biological Chemistry. 2013 Mar 1;288(9):6238-47.
  25. Chen D*, Zhao Z*, Huang Z, Chen DC, Zhu XX, Wang YZ, Yan YW, Tang S, Madhavan S, Ni W, Huang ZP, Li W, Ji W, Shen H, Lin S#, Jiang YZ#. Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone Research. 2018 Apr 4;6:11.
  26. Gu Y*, Lin S*, Li JL et.al. Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. Oncogene. 2012 Jan 26;31(4):469-79. *Equal contribution

其他主要工作成绩（比如获奖情况）：

2020    中山大学附属第一医院柯麟奖

2019    广东省“珠江人才计划”青年拔尖人才

2019    国家优秀青年基金

2019    广东省杰出青年基金

2018      广东省杰出青年医学人才

2017      中山大学“百人计划”II期青年杰出人才

 执业点

中山大学附属第一医院（三级甲等）转化医学研究中心